In 2011 the Food and Drug Administration (FDA) approved anti-vascular endothelial growth
factor (VEGF) therapy, bevacizumab, for intractable melanoma. Within the year …

Cancer of the cervix is the leading cause of cancer death in women worldwide, while in the
developed world the disease accounts for 10% of all cancer deaths [1] but is higher in …

The management of recurrent cervical cancer depends mainly on previous treatment and on
the site and extent of recurrence. Concurrent cisplatin-based chemo-radiation is the …

Radiation was until recently the key and only modality for the routine treatment of locally
advanced cervical carcinoma. However after years of studying multi-modality treatments as …

Several groundbreaking clinical trials with the potential to transform the management
paradigm of both locally advanced and persistent, recurrent, or metastatic cervical cancers …

Background Patients with metastatic, recurrent, or persistent cervical cancer not amenable to
local control and/or distant metastases have a very poor prognosis, only being candidates …

Purpose Vascular endothelial growth factor is a key promoter of tumor progression in
cervical carcinoma. The Gynecologic Oncology Group (GOG) conducted a phase II trial to …

Despite decreases in incidence in the twentieth century, cervical cancer continues to be a
highly morbid disease in the United States. For those diagnosed with locally advanced …

Cervical cancer is a leading cause of cancer deaths in women worldwide. Because of its
association with human papilloma virus infection, as well as the ability to screen for …

OBJECTIVE: The aim of the study was to determine the response rate and response
duration of cervical cancer previously treated by cisplatin (with or without radiation) to a …